Brain atrophy screening

Quibim

Quibim's Brain atrophy screening calculates the volume of brain tissues and morphometry to help classify disease and assess its progression. The suite offers quantitative information on underlying central nervous system disorders, by calculating both the absolute and relative (normalized to intra-cranial volume – ICV) volumes of the grey matter, white matter and cerebrospinal fluid as well as their detailed values in 184 regions. These values are framed in a normative database to be compared with healthy subjects of the same age and gender. The app can be used in the management of patients with Alzheimer’s disease, multiple sclerosis and other diseases.
Product specifications Information source: Vendor
Last updated: May 17, 2020
General
Product name Brain atrophy screening
Company Quibim
Subspeciality Neuro
Modality MR
Disease targeted Alzheimer's, Multiple sclerosis, Parkinson’s disease, Epilepsy, Amyotrophic lateral sclerosis (ALS)
Key-features the volume of grey matter, white matter, cerebrospinal fluid and their distribution, parenchyma fraction
Suggested use Without interference of a radiologist: AI-only diagnosis
Data characteristics
Population Patients with neurological degenerative disease
Input MRI T1 GRE 3D T1 Fast Gradient Echo
Input format
Output One-page structured report: normative bars of brain (sub)region volume
Output format DICOM Secondary Capture / PDF
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically, right after the image acquisition
Processing time > 10 minutes
Certification
CE
Certified, Class IIa , MDD
FDA
No or not yet
Market presence
On market since 01-2019
Distribution channels
Countries present (clinical, non-research use) 8
Paying clinical customers (institutes) 5+
Research/test users (institutes) <5
Pricing
Pricing model License
Based on Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers Magraner MJ, Bosca I, Simó-Castello M, García-Martí G, Alberich-Bayarri A, Álvarez-Cermeño JC, Martí-Bonmatí L, Villar LM, Casanova B (2012). Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology. 2012 Jan; 54(1): 5-12.